◆ NeutralCYTK

Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

GlobeNewswire Inc.·
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Cytokinetics announced that its management team will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company will discuss its cardiovascular biopharmaceutical pipeline, including MYQORZO® (aficamten) for obstructive hypertrophic cardiomyopathy and ongoing development of omecamtiv mecarbil and ulacamten for heart failure treatments.

Read Full Article at GlobeNewswire Inc.
← Back to Financial Intelligence